![Patricia Delaite](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Patricia Delaite
Keine laufenden Positionen mehr
Profil
Patricia Delaite served as an Independent Director at Cantargia AB from 2017 to 2023.
Prior to that, she held the position of Chief Medical Officer at Amal Therapeutics SA and Nouscom AG.
Dr. Delaite holds a doctorate degree from the University of Geneva and an MBA from the University of Lausanne.
Ehemalige bekannte Positionen von Patricia Delaite
Unternehmen | Position | Ende |
---|---|---|
CANTARGIA AB | Direktor/Vorstandsmitglied | 23.05.2023 |
Nouscom AG
![]() Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | - |
Amal Therapeutics SA
![]() Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Patricia Delaite
University of Geneva | Doctorate Degree |
University of Lausanne | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CANTARGIA AB | Health Technology |
Private Unternehmen | 2 |
---|---|
Amal Therapeutics SA
![]() Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
Nouscom AG
![]() Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Health Technology |